VIB Vermögen Gelecekteki Büyüme
Future kriter kontrolleri 0/6
VIB Vermögen's earnings are forecast to decline at 19.3% per annum while its annual revenue is expected to grow at 2.8% per year. EPS is expected to decline by 19.2% per annum. Return on equity is forecast to be 6.7% in 3 years.
Anahtar bilgiler
-19.3%
Kazanç büyüme oranı
-19.2%
EPS büyüme oranı
Real Estate kazanç büyümesi | 93.1% |
Gelir büyüme oranı | 2.8% |
Gelecekteki özkaynak getirisi | 6.7% |
Analist kapsamı | Low |
Son güncelleme | 22 Aug 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Should You Think About Buying VIB Vermögen AG (ETR:VIH1) Now?
Oct 11VIB Vermögen AG (ETR:VIH1) Shares Fly 26% But Investors Aren't Buying For Growth
Sep 20Concerns Surrounding VIB Vermögen's (ETR:VIH1) Performance
May 08When Should You Buy VIB Vermögen AG (ETR:VIH1)?
Dec 20Is VIB Vermögen (ETR:VIH1) Using Too Much Debt?
Jun 21Is Now The Time To Look At Buying VIB Vermögen AG (ETR:VIH1)?
May 30VIB Vermögen AG (ETR:VIH1) Shares Could Be 43% Below Their Intrinsic Value Estimate
Mar 29VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 18Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?
Feb 11Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?
Sep 06Is VIB Vermögen (ETR:VIH1) A Risky Investment?
Oct 15VIB Vermögen (ETR:VIH1) Has Compensated Shareholders With A Respectable 100% Return On Their Investment
Mar 11A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE
Feb 18You Have To Love VIB Vermögen AG's (ETR:VIH1) Dividend
Jan 19Here's What VIB Vermögen AG's (ETR:VIH1) Shareholder Ownership Structure Looks Like
Dec 25Shareholders Of VIB Vermögen (ETR:VIH1) Must Be Happy With Their 94% Return
Dec 06A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE
Nov 18Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 101 | 49 | 70 | 95 | 1 |
12/31/2025 | 92 | 42 | 111 | 97 | 1 |
12/31/2024 | 85 | 38 | 15 | 104 | 1 |
6/30/2024 | 98 | 87 | 68 | 68 | N/A |
3/31/2024 | 100 | 108 | 72 | 72 | N/A |
12/31/2023 | 103 | 130 | 75 | 75 | N/A |
9/30/2023 | 105 | 107 | 73 | 73 | N/A |
6/30/2023 | 108 | 84 | 71 | 71 | N/A |
3/31/2023 | 128 | 76 | N/A | N/A | N/A |
12/31/2022 | 128 | 54 | 68 | 68 | N/A |
9/30/2022 | 126 | 41 | N/A | N/A | N/A |
6/30/2022 | 126 | 49 | 74 | 74 | N/A |
3/31/2022 | 106 | 143 | N/A | N/A | N/A |
12/31/2021 | 102 | 30 | 75 | 75 | N/A |
9/30/2021 | 101 | 54 | N/A | N/A | N/A |
6/30/2021 | 98 | 53 | 69 | 71 | N/A |
3/31/2021 | 96 | 71 | N/A | N/A | N/A |
12/31/2020 | 94 | 66 | 64 | 65 | N/A |
9/30/2020 | 94 | 71 | N/A | N/A | N/A |
6/30/2020 | 93 | 67 | 64 | 64 | N/A |
3/31/2020 | 92 | 64 | N/A | N/A | N/A |
12/31/2019 | 91 | 63 | 69 | 69 | N/A |
9/30/2019 | 90 | 58 | N/A | N/A | N/A |
6/30/2019 | 89 | 60 | 67 | 67 | N/A |
3/31/2019 | 88 | 59 | N/A | N/A | N/A |
12/31/2018 | 87 | 58 | 61 | 61 | N/A |
9/30/2018 | 86 | 58 | N/A | N/A | N/A |
6/30/2018 | 85 | 53 | 61 | 61 | N/A |
3/31/2018 | 85 | 51 | N/A | N/A | N/A |
12/31/2017 | 84 | 52 | N/A | 59 | N/A |
9/30/2017 | 83 | 49 | N/A | N/A | N/A |
6/30/2017 | 82 | 50 | N/A | 57 | N/A |
3/31/2017 | 81 | 50 | N/A | N/A | N/A |
12/31/2016 | 80 | 47 | N/A | 58 | N/A |
9/30/2016 | 79 | 43 | N/A | N/A | N/A |
6/30/2016 | 78 | 44 | N/A | 56 | N/A |
3/31/2016 | 77 | 40 | N/A | N/A | N/A |
12/31/2015 | 75 | 40 | N/A | 54 | N/A |
9/30/2015 | 73 | 37 | N/A | N/A | N/A |
6/30/2015 | 72 | 32 | N/A | N/A | N/A |
3/31/2015 | 71 | 32 | N/A | N/A | N/A |
12/31/2014 | 70 | 31 | N/A | 48 | N/A |
9/30/2014 | 69 | 29 | N/A | N/A | N/A |
6/30/2014 | 68 | 28 | N/A | N/A | N/A |
3/31/2014 | 66 | 27 | N/A | N/A | N/A |
12/31/2013 | 65 | 27 | N/A | 48 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: VIH1's earnings are forecast to decline over the next 3 years (-19.3% per year).
Kazançlar ve Piyasa: VIH1's earnings are forecast to decline over the next 3 years (-19.3% per year).
Yüksek Büyüme Kazançları: VIH1's earnings are forecast to decline over the next 3 years.
Gelir ve Pazar: VIH1's revenue (2.8% per year) is forecast to grow slower than the German market (5.5% per year).
Yüksek Büyüme Geliri: VIH1's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: VIH1's Return on Equity is forecast to be low in 3 years time (6.7%).